Article

Real World Evidence – Current Developments and Perspectives

2022-07-08

Abstract excerpt

Real-world evidence (RWE) is increasingly involved in the early benefit assessment of medicinal drugs. It is expected that RWE will help to speed up approval processes comparable to RWE developments in vaccine research during the COVID-19 pandemic. Definitions of RWE are diverse marking the highly fluid status in this field. So far, RWE comprises information produced from data routinely collected on patient’...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4800b195-a495-5bfc-80ca-beab98e3f70a
DOI: 10.20944/preprints202207.0141.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Real World Evidence – Current Developments and PerspectivesDOI 10.20944/preprints202207.0141.v1Read

Real world evidence (RWE) – a disruptive innovation or the quiet evolution of medical evidence generation?Semantic proximity Read

Methodological Challenges using Routine Clinical Care Data for Real-World Evidence: a Rapid Review utilizing a systematic literature search and focus group discussionSemantic proximity Read

Trust and Trade: Patient Perspectives on the Ethics of Real-World Data MonetisationSemantic proximity Read

Use of real-world evidence in regulatory decisions for traditional Chinese medicine---Current status and futureSemantic proximity Read

Real-World Data and Evidence in Lung Cancer: A Review of Recent DevelopmentsSemantic proximity Read

Data quality reporting in multi-database pharmacoepidemiologic studies: a scoping review and a proposal for a harmonised classificationSemantic proximity Read

Trust and Trade: Patient Perspectives on the Ethics of Real-World Data MonetisationSemantic proximity Read

How the HTAR will contribute to a value-based decision making for medicinal products across the EUSemantic proximity Read

The Current Landscape of Clinical TrialsSemantic proximity Read

INSIGHT: A Tool for Fit-for-Purpose Evaluation and Quality Assessment of Observational Data Sources for Real World Evidence on Medicine and Vaccine SafetySemantic proximity Read

U.S. Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018Semantic proximity Read

Characteristics and data reporting of rare disease clinical trials: Getting better but still room for improvementSemantic proximity Read